METROPOLIS

Metropolis Healthcare Ltd.
Registered Office: 4th Floor, East Wing, Plot-254 B, Nirlon House, Dr. Annie Besant Rd, Worli, Mumbai - 400030, Maharashtra, India.
Corporate Office & Global Reference Laboratory:
4th Floor, Commercial Bldg-1A, Kohinoor Mall, Vidyavihar (W), Mumbai - 400 070. CIN: L73100MH2000PLC192798.

Ref: MHL/Sec&Legal/2026-27/56 **November 03, 2026**

To,

BSE Limited
Scrip Code: 542650

National Stock Exchange of India Limited
Scrip Symbol: METROPOLIS

Dear Sir/Madam,

Sub: Outcome of Board Meeting held on Tuesday, November 03, 2026

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ('SEBI Listing Regulations'), this is to inform you that the Board of Directors of the Company, at its meeting held Today i.e., Tuesday, November 03, 2026, has, *inter alia,* considered the following matters:

1. Financial Results

Approved the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2026, and noted the limited review report thereon, issued by the Statutory Auditors of the Company. The financial results together with the limited review report are enclosed herewith. The financial results are also being made available on the Company's website at www.metropolisindia.com.

2. Declaration of Interim Dividend

Declared Interim Dividend of INR 1/- (Indian Rupee One only) per equity share of face value of INR 2/- (Indian Rupees Two only) each for the financial year 2026-27. The record date for the purpose of payment of Interim Dividend shall be Monday, November 09, 2026. The Interim Dividend will be paid within 30 days of its declaration.

The meeting commenced at 02:15 p.m. (IST) and concluded at 05:50 p.m. (IST).

You are requested to take the above information on record.

Thanking you,
Yours faithfully,

For Metropolis Healthcare Limited

Kamlesh Chandrashekhar Kulkarni

Digitally signed by Kamlesh Chandrashekhar Kulkarni
DN: c=IN, st=Maharashtra, 2.5.4.20=7b2c373c96d15b9bcfca30002f2fbd0e3a8a7775221bd4075c13677c37ee6541, postalCode=422004, street=50 Chandrashekhar Kulkarni Plot No47 Vrundavan Nagar Dindori Road Near Gajanan Maharaj Mandir Mhasrul Nashik, pseudonym=ca57b98d46ce46314e68e0e138a62c3, title=1552, serialNumber=2d68a0037baac42820279c8effc9ae2073aa3f9ef35e80715cbcb9b2ac6bcc68, o=Personal, cn=Kamlesh Chandrashekhar Kulkarni
Date: 2026.11.03 19:01:40 +05'30'

Kamlesh C Kulkarni
Head - Legal & Secretarial

Encl: a/a

Deloitte
Haskins & Sells
Chartered Accountants LLP

Chartered Accountants
One International Center
Tower 3, 27th-32nd Floor
Senapati Bapat Marg
Elphinstone Road (West)
Mumbai-400 013
Maharashtra, India

Tel: 22 6185 4000
Fax: 22 6185 4101

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF METROPOLIS HEALTHCARE LIMITED

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **METROPOLIS HEALTHCARE LIMITED** ("the Company"), for the quarter and six months ended September 30, 2026 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Deloitte
Haskins & Sells
Chartered Accountants LLP

5. The standalone financial results of the Company for the quarter ended June 30, 2026, for the quarter and six months ended September 30, 2025 and for the year ended March 31, 2026 included in the Statement, were reviewed / audited by another auditor who expressed an unmodified conclusion / opinion on those statements on August 04, 2026, November 04, 2025 and May 13, 2026, respectively.

   Our conclusion on the statement is not modified in respect of this matter.

For **Deloitte Haskins & Sells Chartered Accountants LLP**
Chartered Accountants
(Firm's Registration No. 117364W/W-100739)



Pallavi Sharma
Partner
Membership No. 113861
UDIN: 26113861XYCPHV3828

Place: Mumbai
Date: November 03, 2026

METROPOLIS

Metropolis Healthcare Limited

Registered and Corporate Office: 4th Floor, East Wing, Plot 254 B, Nirlon House, Dr. Annie Besant Road, Worli. Mumbai - 400030, Maharashtra, India

CIN:L73100MH2000PLC192798

Email: support@metropolisindia.com ; **Contact No.**: 8422 801 801; **Website:** www.metropolisindia.com

Global Reference Lab: 4th Floor Commercial Bldg. - 1A, Kohinoor Mall, Vidyavihar (West), Mumbai - 400070, Maharashtra, India

Statement of unaudited Standalone Financial Results for the quarter and six months ended September 30, 2026

(Rs. in million)

Sr. No.	Particulars	Quarter ended			Six Months ended		Year ended
		September 30, 2026	June 30, 2026	September 30, 2025	September 30, 2026	September 30, 2025	March 31, 2026
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
	Continuing operations						
1	**Income**						
	a) Revenue from operations	4,169.34	3,722.84	3,554.57	7,892.18	6,787.27	13,654.72
	b) Other income	89.88	51.86	25.20	141.74	52.99	163.31
	Total Income	**4,259.22**	**3,774.70**	**3,579.77**	**8,033.92**	**6,840.25**	**13,818.03**
2	**Expenses**						
	a) Cost of materials consumed	725.16	684.74	682.14	1,409.90	1,295.72	2,527.18
	b) Laboratory testing charges	92.13	67.68	40.27	159.81	80.82	180.18
	c) Employee benefits expense	840.27	852.43	753.93	1,692.70	1,476.62	2,974.38
	d) Finance costs	55.46	47.73	39.66	103.19	82.60	191.87
	e) Depreciation and amortisation expense	283.17	278.06	277.88	561.23	556.47	1,161.68
	f) Other expenses	1,324.49	1,180.30	1,166.61	2,504.79	2,254.90	4,590.75
	Total Expenses	**3,320.68**	**3,110.94**	**2,960.49**	**6,431.62**	**5,747.13**	**11,626.04**
3	**Profit before exceptional items and tax (1) - (2)**	**938.54**	**663.76**	**619.28**	**1,602.30**	**1,093.12**	**2,191.99**
4	**Exceptional Items (Refer note 6)**	-	-	-	-	-	**79.57**
5	**Profit before tax (3) - (4)**	**938.54**	**663.76**	**619.28**	**1,602.30**	**1,093.12**	**2,112.42**
6	**Tax expenses**						
	Current tax :						
	-for the year:	240.70	168.78	173.53	409.48	305.29	571.86
	-tax adjusted for earlier years:	-	-	-	-	3.70	3.70
	Deferred tax (credit)	10.33	(11.56)	(19.15)	(1.23)	(34.36)	(34.55)
	Total tax expenses	**251.03**	**157.22**	**154.38**	**408.25**	**274.63**	**541.01**
7	**Profit for the period / year from continuing operations (5) - (6)**	687.51	506.54	464.90	1,194.05	818.49	1,571.41
8	**Discontinued Operations (Refer note 4)**						
	Profit/(Loss) before tax from discontinued operation	-	(0.95)	1.91	(0.95)	4.89	4.57
	Tax expense of discontinued operations	-	(0.24)	0.48	(0.24)	1.23	1.15
	Profit/(Loss) after tax from discontinued operations	**-**	**(0.71)**	**1.43**	**(0.71)**	**3.66**	**3.42**
9	**Profit for the period/year (7) + (8)**	**687.51**	**505.83**	**466.33**	**1,193.34**	**822.15**	**1,574.83**
10	**Other comprehensive income**						
	Items that will not be reclassified to profit and loss (net of tax)	(2.90)	0.44	(23.75)	(2.46)	(27.95)	(1.75)
	Items that will be reclassified to profit and loss (net of tax)	-	-	-	-	-	-
	Other comprehensive income/(loss) for the period /year (net of tax)	**(2.90)**	**0.44**	**(23.75)**	**(2.46)**	**(27.95)**	**(1.75)**
11	**Total comprehensive income (9) + (10)**	**684.61**	**506.27**	**442.58**	**1,190.88**	**794.20**	**1,573.08**
12	Paid-up equity share capital (face value - Rs. 2 per share)	414.91	414.67	103.62	414.91	103.62	414.66
13	Other equity	-	-	-	-	-	13,476.39
14	**Earning per share from continuing operation#**						
	Earnings per share (Face value of Rs.2 each) basic- (Rs.)	3.32	2.44	2.25	5.76	3.96	7.60
	Earnings per share (Face value of Rs.2 each) diluted - (Rs.)	3.29	2.44	2.24	5.73	3.95	7.60
15	**Earning per share from discontinuing operation#**						
	Earnings per share (Face value of Rs.2 each) basic- (Rs.)	-	-*	-*	-*	0.01	0.02
	Earnings per share (Face value of Rs.2 each) diluted - (Rs.)	-	-*	-*	-*	0.01	0.02
16	**Earning per share from continuing and discontinuing operation#**						
	Earnings per share (Face value of Rs.2 each) basic- (Rs.)	3.32	2.44	2.25	5.76	3.97	7.62
	Earnings per share (Face value of Rs.2 each) diluted - (Rs.)	3.29	2.44	2.24	5.73	3.95	7.62

not annualised for the quarters

*Earnings per share (basic and diluted) from discontinued operations is less than Rs.0.01 per equity share.

See accompanying notes to the unaudited standalone financial results

Metropolis Healthcare Limited Mumbai

Deloitte Haskins & Sells Chartered Accountants LLP Mumbai

METROPOLIS

NOTES:

1 The above results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on November 03, 2026. The limited review, as required under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, has been completed by the Statutory Auditors for the quarter ended September 30, 2026 and they have expressed an unmodified conclusion on the aforesaid results.

2 These financial results have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.

3 The Company has changed the presentation of financial information from Rs. in Lakhs to Rs. in Million with effect from the quarter ended June 30, 2026. Accordingly, the comparative figures have been suitably restated to Rs. in Million for the purpose of comparability and has no impact on the profit for the period, other comprehensive income, net worth or earnings per share of any period presented.

4 The Board of Directors of the Company at their meeting held on February 04, 2026 had approved the transfer of External Quality Assessment Services Business ('EQAS Division'), to Metropolis Quality Solutions Private Limited, a subsidiary of the Company as a going concern, on a slump sale basis. Consequently the proposed transfer of the EQAS division had been disclosed as discontinued operations in accordance with Ind AS 105 "Non - current Assets Held for Sale and Discontinued Operations".

The Company has executed a Business Transfer Agreement (BTA), effective August 27, 2026 and transferred its EQAS division to Metropolis Quality Solutions Private Limited. Accordingly, the financial results for the quarter ended June 30, 2026 and September 30, 2026 and six months ended September 30, 2026 continue to present the results of the discontinued operation separately. The figures for the comparative previous period for the quarter and six months ended September 30, 2025 have been restated to give effect to the presentation requirement of Ind AS 105 "Non - current Assets Held for Sale and Discontinued Operations".

Key Financial information of Discontinued Operations:

Particulars	Quarter ended			Six Months ended		Year ended
	September 30, 2026	June 30, 2026	September 30, 2025	September 30, 2026	September 30, 2025	March 31, 2026
Total Income	-	0.15	2.56	0.15	6.19	7.19
Total Expense	-	1.10	0.65	1.10	1.30	2.62
Profit before tax	-	(0.95)	1.91	(0.95)	4.89	4.57
Total tax expenses	-	(0.24)	0.48	(0.24)	1.23	1.15
Net profit for the period	-	(0.71)	1.43	(0.71)	3.66	3.42

5 During the quarter, the Nomination and Remuneration Committee of the Company approved grant of :
a) 1,380 Restricted Stock Units (RSU) , pursuant to the Metropolis Restrictive Stock Unit Plan - 2025 to eligible employees of the Company.
b) 20,500 Employees Stock Options, pursuant to the Metropolis Employees Stock Option Plan - 2025 to eligible employees of the Company.

Further, in respect of Metropolis Restrictive Stock Unit Plan - 2020, 4,200 and 1,21,912 RSU's were alloted during the quarter ended June 30, 2026 and September 30, 2026 respectively.

6 During the previous year, pursuant to the notification and subsequent finalisation of the Central Rules under the Labour Codes by the Government of India, the Company assessed the financial impact of the revised regulatory framework, including the Code on Social Security, 2020, based on detailed evaluation of the notified provisions, professional advice, and actuarial valuation. Based on this assessment, the Company have recognised an estimated liability towards gratuity and leave encashment for past service cost aggregating to Rs. 79.57 million for the year ended March 31, 2026. The total impact has been disclosed as an exceptional item in the financial results.

7 The Company had issued and allotted 15,54,95,826 Bonus Equity Shares in the ratio of 3:1, i.e., Three (3) new fully paid-up Equity Shares of face value of Rs. 2/- each for every One (1) existing fully paid-up Equity Share of face value of Rs.2/- cach. The Board of Directors at their meeting held on February 04, 2026 approved issuance of bonus shares, which was approved by the shareholders on March 08, 2026.

8 The Board of the Directors of the Company have approved interim dividend of Re.1 per equity shares on 20,75,28,996 shares (face value of Rs. 2 each) at their meeting held on November 03, 2026.

9 Based on the nature of the business and line of products/ services, there is only one reportable segment - Pathology service.

10 The standalone financial results of the Company are available for investors at www.metropolisindia.com, www.nseindia.com and www.bseindia.com.

For Metropolis Healthcare Limited

Ameera Shah
Chairperson and Wholetime Director
DIN: 00208095
Place: Mumbai
Date: November 03, 2026

Metropolis Healthcare Limited Mumbai

Deloitte Haskins & Sells Chartered Accountants LLP Mumbai

Metropolis Healthcare Limited
Standalone Balance Sheet as at September 30, 2026

(Rs. in million)

Particulars	As at September 30, 2026	As at March 31, 2026
	Unaudited	Audited
I. ASSETS		
Non-current assets		
Property, plant and equipment	1,813.66	1,748.03
Right-of-use assets	1,904.31	1,643.64
Goodwill	4,154.25	4,154.25
Other intangible assets	3,748.99	3,806.29
Financial assets		
i) Investments	3,516.03	3,489.57
ii) Loans	13.65	13.63
iii) Other financial assets	206.94	179.47
Non-current tax assets (net)	113.78	155.16
Other non-current assets	19.51	52.64
Total Non-current assets	**15,491.12**	**15,242.68**
Current assets		
Inventories	350.77	322.10
Financial assets		
i) Investments	2,601.34	1,347.76
ii) Trade receivables	1,399.27	1,188.70
iii) Cash and cash equivalents	237.84	200.64
iv) Bank balance other than cash and cash equivalents	18.18	4.85
v) Loans	8.48	7.98
vi) Other financial assets	131.63	113.68
Other current assets	247.52	276.22
Asset held for sale (Refer note 4)	-	0.19
Total Current assets	**4,995.03**	**3,462.12**
TOTAL ASSETS	**20,486.15**	**18,704.80**
II. EQUITY AND LIABILITIES		
Equity		
Equity share capital	414.91	414.66
Other equity	14,582.08	13,476.39
Total Equity	**14,996.99**	**13,891.05**
Non- current liabilities		
Financial liabilities		
i) Lease liabilities	1,463.25	1,182.63
ii) Other financial liabilities	14.40	13.77
Provisions	294.45	291.89
Deferred tax liabilities (net)	669.26	671.32
Total Non-current liabilities	**2,441.36**	**2,159.61**
Current liabilities		
Financial liabilities		
i) Lease liabilities	631.73	636.71
ii) Trade payables		
- Total outstanding due to micro enterprises and small enterprises	74.96	34.36
- Total outstanding dues of creditors other than micro enterprises and small enterprises	1,303.29	1,118.31
iii) Other financial liabilities	186.27	154.97
Other current liabilities	167.80	171.05
Provisions	136.01	132.67
Current tax liabilities (net)	547.74	406.07
Total Current liabilities	**3,047.80**	**2,654.14**
TOTAL LIABILITIES	**5,489.16**	**4,813.75**
TOTAL EQUITY AND LIABILITIES	**20,486.15**	**18,704.80**

Metropolis Healthcare Limited Mumbai

Deloitte Haskins & Sells Chartered Accountants LLP Mumbai

METROPOLIS

Metropolis Healthcare Limited
Standalone Statement of cash flows for the six months ended September 30, 2026

(Rs. in million)

	Particulars	Six months ended	
		September 30, 2026	September 30, 2025
		(Unaudited)	(Unaudited)
A	**Cash flows from operating activities**		
	Profit before tax	1,601.37	1,098.01
	Adjustments for :		-
	Depreciation and amortisation expenses	561.23	556.49
	Interest paid on lease liabilities	102.56	82.56
	Fair value (loss)/gain on mutual funds measured at FVTPL (net)	(41.99)	23.12
	Allowance for trade receivables (net)	65.89	109.31
	Share based payments (net)	122.20	39.70
	Interest on deferred purchase consideration	0.63	0.04
	Unrealised foreign exchange (gain) / loss (net)	(24.02)	(13.51)
	Gain on asset held for sale	(12.31)	-
	Sundry balances written back	(0.91)	(0.00)
	Net gain on redemption of mutual fund investments	(21.83)	(35.39)
	Credit impaired trade receivables written off	0.42	-
	Loss/(Profit) on sale of Property, Plant and Equipment (net)	0.45	-
	Interest income	(9.78)	(7.46)
	Interest income on income tax refund	(6.77)	-
	Gain on Termination of Leases	(0.70)	(0.39)
	Operating profit before working capital changes	**2,336.44**	**1,852.46**
	Working capital adjustments:		
	(Increase)/Decrease in inventories	(28.67)	29.08
	(Increase) in loans (current and non-current)	-	(4.42)
	Decrease/(Increase) in other assets (current and non-current)	27.84	(102.66)
	(Increase) in trade receivables	(252.43)	(318.09)
	(Increase) in other financial assets	(55.65)	(17.75)
	Increase in provisions	5.91	17.97
	Increase/(Decrease) in trade payables	226.09	(105.57)
	Increase/(Decrease) in other financial liabilities	28.12	(25.65)
	(Decrease) in other current liabilities	(3.88)	(5.43)
	Cash flows generated from operating activities	**2,283.77**	**1,319.94**
	Income taxes paid (net)	(222.72)	(184.70)
	Net cash flows generated from operating activities (A)	**2,061.05**	**1,135.24**
B	**Cash flows from investing activities**		
	Purchase of property, plant and equipment	(123.59)	(138.32)
	Purchase of other intangible assets	(76.14)	(174.71)
	Purchase of current investments	(3,187.65)	(2,231.07)
	Proceeds from sale of current investments	1,997.89	2,757.46
	Investments in subsidiaries through equity instruments	-	(926.41)
	Investments in subsidiaries through Equity	-	(0.20)
	Interest received	9.25	1.51
	Proceeds from maturity of deposits (having original maturity of more than three months)	2.47	21.07
	Net investments in deposits (having original maturity of more than three months)	(5.56)	(26.63)
	Net cash flows (used in) investing activities (B)	**(1,383.33)**	**(717.30)**
C	**Cash flows from financing activities**		
	Principal payment of lease liabilities	(330.78)	(354.55)
	Proceeds from exercise of options under RSU 2020 scheme	0.15	0.01
	Interest paid on lease liabilities	(102.56)	(82.56)
	Payment of interim dividend	(207.33)	-
	Net cash flows (used in) financing activities (C)	**(640.52)**	**(437.10)**
	Net Increase/(decrease) in cash and cash equivalents (A) + (B) + (C)	**37.20**	**(19.15)**
	Cash and cash equivalents at the beginning of the period	**200.64**	**226.84**
	Add: Effect of exchange differences on balances with banks in foreign currency	-	(0.98)
	Cash and cash equivalents at the end of the period	**237.84**	**206.70**

Note:
The above statement of Cash flows has been prepared under the 'Indirect Method' as set out in Ind AS 7, 'Statement of Cash Flows'.

Metropolis Healthcare Limited Mumbai

Deloitte Haskins & Sells Chartered Accountants LLP Mumbai

Deloitte
Haskins & Sells
Chartered Accountants LLP

Chartered Accountants
One International Center
Tower 3, 27th-32nd Floor
Senapati Bapat Marg
Elphinstone Road (West)
Mumbai-400 013
Maharashtra, India

Tel: 22 6185 4000
Fax: 22 6185 4101

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF
METROPOLIS HEALTHCARE LIMITED

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **METROPOLIS HEALTHCARE LIMITED** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the quarter and six months ended September 30, 2026 ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities:

Parent	Metropolis Healthcare Limited
Subsidiaries	Ekopath Metropolis Lab Services Private Limited
	Amin's Pathology Laboratory Private Limited
	DAPIC Metropolis Healthcare Private Limited (Formerly known as Metropolis Histoxpert Digital Services Private Limited)
	Centralab Healthcare Services Private Limited
	Metropolis Healthcare (Mauritius) Limited
	Metropolis Healthcare Lanka (Pvt) Limited (Formerly known as Nawaloka Metropolis Laboratories Private Limited, Sri Lanka)
	Core Diagnostics Private Limited

	Metropolis Foundation
	Scientific Metropolis Pathology Private Limited (Formerly known as Metropolis Clinical Pathology Private Limited)
	Metropolis Quality Solution Private Limited
Step-down Subsidiaries	Metropolis Bramser Lab Services (Mtius) Limited
	Metropolis Healthcare Ghana Limited
	Metropolis Star Lab Kenya Limited
	Metropolis Healthcare (Tanzania) Limited
	Metropolis Healthcare Uganda Limited

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. We did not review the interim financial information of two subsidiaries included in the consolidated unaudited financial results, whose interim financial information reflect total assets of Rs. 1,120.39 million as at September 30, 2026 and, total revenues of Rs. 351.72 million and Rs 667.94 million for the quarter and six months ended September 30, 2026 respectively, total net profit after tax of Rs. 74.95 million and Rs. 112.17 million for the quarter and six months ended September 30, 2026 respectively and total comprehensive income of Rs 81.07 million and Rs 143.15 million for the quarter and six months ended September 30, 2026 respectively and net cash inflows of Rs. 35.69 million for the six months ended September 30, 2026, as considered in the Statement. These interim financial information have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, joint ventures and associates, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

   Subsidiaries referred to above are located outside India whose interim financial information has been prepared in accordance with the accounting principles generally accepted in their respective countries and which have been reviewed by other auditors under generally accepted auditing standards applicable in their respective countries. The Parent Company's Management has converted the interim financial information of such subsidiaries located outside India from the accounting principles generally accepted in their respective countries to the accounting principles generally accepted in India. We have reviewed these conversion adjustments made by the Parent Company's Management. Our conclusion in so far as it relates to the amounts and disclosures included in respect of these subsidiaries located outside India is based on the report of such other auditors and the conversion adjustments prepared by the Management of the Parent Company and reviewed by us.

   Our conclusion on the Statement is not modified in respect of these matters.

7. The consolidated unaudited financial results includes the interim financial information of seven subsidiaries which have not been reviewed by their auditors, whose interim financial information reflect total assets of Rs. 539.03 million as at September 30, 2026 and, total revenue of Rs. 143.77 million and Rs. 282.48 million for the quarter and six months ended September 30, 2026 respectively, total profit/(loss) after tax of Rs. (2.14) million and Rs. 8.21 million for the quarter and six months ended September 30, 2026 respectively and total comprehensive income of Rs. 2.27 million and Rs. 14.17 million for the quarter and six months ended September 30, 2026 respectively and net cash inflows of Rs. 32.03 million for the six months ended September 30, 2026, as considered in the Statement. According to the information and explanations given to us by the Management, these interim financial information are not material to the Group.

   Our Conclusion on the Statement is not modified in respect of our reliance on the interim financial information certified by the Management.

8. The consolidated financial results of the Company for the quarter ended June 30, 2026, for the quarter and six months ended September 30, 2025 and for the year ended March 31, 2026 included in the Statement, were audited/ reviewed by another auditor who expressed an unmodified opinion/ conclusion on those statements on August 04, 2026, November 04, 2025 and May 13, 2026, respectively.

   Our conclusion on the statement is not modified in respect of this matter.

For **Deloitte Haskins & Sells Chartered Accountants LLP**
Chartered Accountants
(Firm's Registration No. 117364W/W-100739)



Pallavi Sharma
Partner
Membership No. 113861
UDIN: 26113861VMKCWV7348

Place: Mumbai
Date: November 03, 2026

Metropolis Healthcare Limited

Registered and Corporate Office: 4th Floor, East Wing, Plot 254 B, Nirlon House, Dr. Annie Besant Road, Worli. Mumbai - 400030, Maharashtra, India
CIN:L73100MH2000PLC192798
Contact No.: 8422 801 801
Email: support@metropolisindia.com
Website: www.metropolisindia.com
Global Reference Lab: 4th Floor Commercial Bldg. - 1A, Kohinoor Mall, Vidyavihar (West), Mumbai - 400070, Maharashtra, India

Statement of unaudited Consolidated Financial Results for the quarter and six months ended September 30, 2026

(Rs. in million)

Sr. No.	Particulars	Quarter ended			Six months ended		Year ended
		September 30, 2026	June 30, 2026	September 30, 2025	September 30, 2026	September 30, 2025	March 31, 2026
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	**Income**						
	a) Revenue from operations	4,968.21	4,502.15	4,291.91	9,470.36	8,152.55	16,458.46
	b) Other income	84.92	51.02	8.91	135.94	84.07	255.84
	Total Income	**5,053.13**	**4,553.17**	**4,300.82**	**9,606.30**	**8,236.62**	**16,714.30**
2	**Expenses**						
	a) Cost of materials consumed	938.29	871.01	877.48	1,809.30	1,667.98	3,245.17
	b) Laboratory testing charges	92.79	63.30	49.67	156.09	106.41	230.05
	c) Employee benefits expense	1,057.96	1,069.76	953.93	2,127.72	1,876.73	3,773.64
	d) Finance costs	69.86	61.80	56.82	131.66	108.80	245.44
	e) Depreciation and amortisation expense	330.47	324.03	324.08	654.50	632.53	1,337.22
	f) Other expenses	1,538.95	1,386.15	1,328.58	2,925.10	2,521.61	5,201.13
	Total Expenses	**4,028.32**	**3,776.05**	**3,590.56**	**7,804.37**	**6,914.06**	**14,032.65**
3	**Profit before exceptional items and tax (1) - (2)**	**1,024.81**	**777.12**	**710.26**	**1,801.93**	**1,322.56**	**2,681.65**
4	**Exceptional items (Refer note 6)**	-	-	-	-	-	89.90
5	**Profit before tax (3) - (4)**	**1,024.81**	**777.12**	**710.26**	**1,801.93**	**1,322.56**	**2,591.75**
6	**Tax expenses**						
	Current tax:						
	- for the year :	263.98	210.36	202.45	474.34	375.06	733.21
	- tax adjusted for earlier years :	-	(0.16)	-	(0.16)	3.70	3.70
	Deferred tax (credit)	6.00	(1.91)	(21.09)	4.09	(37.55)	(56.98)
	Total tax expenses	**269.98**	**208.29**	**181.36**	**478.27**	**341.21**	**679.93**
7	**Profit for the period / year (5) –(6)**	**754.83**	**568.83**	**528.90**	**1,323.66**	**981.35**	**1,911.82**
8	**Other comprehensive income**						
	Items that will not be reclassified to profit and loss (net of tax)	(1.26)	1.29	(18.06)	0.03	(22.48)	4.10
	Items that will be reclassified to profit and loss (net of tax)	9.37	26.95	38.02	36.32	20.65	44.10
	Other comprehensive income/(loss) for the period /year (net of tax)	**8.11**	**28.24**	**19.96**	**36.35**	**(1.83)**	**48.20**
9	**Total comprehensive income (7) + (8)**	**762.94**	**597.07**	**548.86**	**1,360.01**	**979.52**	**1,960.02**
10	**Profit attributable to:**						
	Owners of the Company	753.38	566.67	526.68	1,320.05	977.29	1,900.17
	Non-controlling interest	1.45	2.16	2.22	3.61	4.07	11.65
11	**Other comprehensive income attributable to:**						
	Owners of the Company	8.14	28.23	20.04	36.37	(1.76)	48.18
	Non-controlling interest	(0.03)	0.01	(0.08)	(0.02)	(0.07)	0.02
12	**Total comprehensive income attributable to:**						
	Owners of the Company	761.52	594.90	546.72	1,356.42	975.53	1,948.35
	Non-controlling interest	1.42	2.17	2.14	3.59	3.99	11.67
13	Paid-up equity share capital (face value - Rs. 2 per share)	414.91	414.67	103.62	414.91	103.62	414.66
14	Other equity (including Non-controlling interest)	-	-	-	-	-	14,716.95
15	Earnings per share (Face value of Rs.2 each) basic-	3.64	2.73	2.54	6.37	4.72	9.19
	Earnings per share (Face value of Rs.2 each) diluted - (Rs.)*	3.60	2.73	2.53	6.33	4.70	9.19

(*not annualised for the quarters)

See accompanying note to the unaudited consolidated financial results

Metropolis Healthcare Limited Mumbai

Deloitte Haskins & Sells Chartered Accountants LLP Mumbai

METROPOLIS

NOTES:

1 Metropolis Healthcare Limited (the 'Company' or the 'Parent') and its subsidiaries (referred collectively as the 'Group') are primarily involved in providing pathology and related healthcare services.

2 The above results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on November 03, 2026. The limited review, as required under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, has been completed by the Statutory Auditors for the quarter ended September 30, 2026 and they have expressed an unmodified conclusion on the aforesaid results.

3 These Consolidated financial results have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.

4 The Group has changed the presentation of financial information from Rs. in Lakhs to Rs. in Million with effect from the quarter ended June 30, 2026. Accordingly, the comparative figures have been suitably restated in Rs. Millions for the purpose of comparability and has no impact on the profit for the period, other comprehensive income, net worth or earnings per share of any period presented

5 During the quarter ended, the Nomination and Remuneration Committee of the Company approved grant of :
a) 1,380 Restricted Stock Units (RSU) , pursuant to the Metropolis Restrictive Stock Unit Plan — 2025 to eligible employees of the Company.
b) 20,500 Employees Stock Options, pursuant to the Metropolis Employees Stock Option Plan — 2025 to eligible employees of the Company.

Further, in respect of Metropolis Restrictive Stock Unit Plan - 2020, 4,200 and 1,21,912 RSU's were allotted during the quarter ended June 30, 2026 and September 30, 2026 respectively.

6 During the previous year, pursuant to the notification and subsequent finalisation of the Central Rules under the Labour Codes by the Government of India, the Parent Company and its Indian subsidiaries assessed the financial impact of the revised regulatory framework, including the Code on Social Security, 2020, based on detailed evaluation of the notified provisions, professional advice, and actuarial valuation. Based on this assessment, the Company have recognised an estimated liability towards gratuity and leave encashment for past service cost aggregating to Rs. 89.90 million for the year ended March 31, 2026. The total impact has been disclosed as an exceptional item in the financial results.

7 The Company had issued and allotted 15,54,95,826 Bonus Equity Shares in the ratio of 3:1, i.e., Three (3) new fully paid-up Equity Shares of face value of Rs. 2/- each for every One (1) existing fully paid-up Equity Share of face value of Rs. 2/- each. The Board of Directors at their meeting held on February 04, 2026 approved issuance of bonus shares, which was approved by the shareholders on March 08, 2026.

8 The Board of the Directors of the Company have approved interim dividend of Re.1 per equity shares on 20,75,28,996 shares (face value of Rs. 2 each) at their meeting held on November 03, 2026.

9 Based on the nature of the business and line of products/ services, there is only one reportable segment - Pathology service.

10 The Consolidated financial results of the Group are available for investors at www.metropolisindia.com, www.nseindia.com and www.bseindia.com.

For Metropolis Healthcare Limited

Ameera Shah
Chairperson and Wholetime Director
DIN: 00208095
Place: Mumbai
Date: November 03, 2026

Metropolis Healthcare Limited Mumbai

Deloitte Haskins & Sells Chartered Accountants LLP Mumbai

METROPOLIS

Metropolis Healthcare Limited
Consolidated Balance Sheet as at September 30, 2026

(Rs. in million)

Particulars	As at September 30, 2026 (Unaudited)	As at March 31, 2026 (Audited)
I. ASSETS		
Non-current assets		
Property, plant and equipment	2,220.13	2,152.99
Right-of-use assets	2,302.44	1,947.15
Goodwill	6,602.95	6,602.49
Other intangible assets	5,240.23	5,308.30
Financial assets		
i) Investments	17.53	17.53
ii) Other financial assets	232.92	205.51
Non-current tax assets (net)	341.96	335.64
Deferred tax assets (net)	63.83	71.66
Other non-current assets	21.95	53.15
Total Non-current assets	**17,043.94**	**16,694.42**
Current assets		
Inventories	510.48	454.94
Financial assets		
i) Investments	2,693.61	1,406.46
ii) Trade receivables	1,841.75	1,702.85
iii) Cash and cash equivalents	686.67	547.84
iv) Bank balance other than cash and cash equivalents	97.02	75.35
v) Loans	-	-
v) Other financial assets	145.00	126.81
Other current assets	389.31	371.88
Total Current assets	**6,363.84**	**4,686.13**
TOTAL ASSETS	**23,407.78**	**21,380.55**
II. EQUITY AND LIABILITIES		
Equity		
Equity share capital	414.91	414.66
Other equity	16,000.50	14,716.95
Equity attributable to equity holders of the Company	**16,415.41**	**15,131.61**
Non-controlling Interests	117.53	113.94
Total Equity	**16,532.94**	**15,245.55**
Non- current liabilities		
Financial liabilities		
i) Borrowings	0.06	-
i) Lease liabilities	1,763.91	1,382.65
ii) Other financial liabilities	15.03	14.28
Provisions	341.58	341.58
Deferred tax liabilities (net)	1,040.28	1,056.27
Total Non-current liabilities	**3,160.86**	**2,794.78**
Current Liabilities		
Financial Liabilities		
i) Borrowings	170.10	187.31
i) Lease liabilities	747.04	749.15
ii) Trade payables		
- Total outstanding due to micro enterprises and small enterprises	91.32	72.13
- Total outstanding dues of creditors other than micro enterprises and small enterprises	1,378.24	1,222.06
iii) Other financial liabilities	285.39	233.89
Other current liabilities	274.99	270.08
Provisions	152.70	142.38
Current tax liabilities (net)	614.20	463.22
Total Current liabilities	**3,713.98**	**3,340.22**
Total Liabilities	**6,874.84**	**6,135.00**
TOTAL EQUITY AND LIABILITIES	**23,407.78**	**21,380.55**

Metropolis Healthcare Limited Mumbai

Deloitte Haskins & Sells Chartered Accountants LLP Mumbai

Metropolis Healthcare Limited
Consolidated Statement of cash flows for the six months ended September 30, 2026

(Rs. in million)

	Particulars	Six Months ended	
		September 30, 2026	September 30, 2025
		(Unaudited)	(Unaudited)
A	**Cash flows from operating activities**		
	Profit before tax	1,801.93	1,322.56
	Adjustments for :		-
	Depreciation and amortisation expense	654.50	632.53
	Loss on sale of property plant and equipments (net)	0.92	2.46
	Gain on termination of leases	(0.70)	(0.90)
	Liabilities no longer required written back	2.85	-
	Sundry balances written back	(0.91)	(0.19)
	Provision for bad and doubtful debts (net)	100.42	117.82
	Net gain on redemption of mutual fund investments	(23.40)	(38.03)
	Unrealised foreign exchange loss (net)	(29.23)	(13.51)
	Share based payments expenses	121.80	39.70
	Bad debts written off	0.42	1.19
	Interest income	(18.12)	(10.19)
	Interest income on income tax refund	(7.71)	(0.32)
	Fair value (loss)/gain on mutual funds measured at FVTPL (net)	(42.99)	23.88
	Interest expenses on borrowings	7.94	13.73
	Interest on deferred purchase consideration	0.88	0.28
	Interest on lease liabilities	122.85	94.80
	Operating profit before working capital changes	**2,691.45**	**2,185.81**
	Working capital adjustments:		
	(Increase)/Decrease in inventories	(55.54)	59.01
	(Increase) in trade receivables	(239.73)	(382.84)
	(Increase) in other assets (current and non current)	(17.17)	(168.78)
	(Increase) in other financial assets (current and non current)	(60.33)	(18.71)
	Increase in provisions (current and non current)	10.32	23.01
	Increase/(Decrease) in trade payables	176.29	(63.56)
	Increase/(Decrease) in other financial liabilities (current and non current)	50.67	(19.37)
	Increase/(Decrease) in other liabilities	4.90	(48.69)
	Cash flows generated from operating activities	**2,560.86**	**1,565.88**
	Income taxes (paid) (net)	(334.03)	(274.58)
	Net cash flows generated from operating activities (A)	**2,226.83**	**1,291.30**
B	**Cash flows from investing activities**		
	Purchase of property, plant and equipment	(154.69)	(249.53)
	Purchase of other intangible assets	(77.62)	(173.86)
	Deferred purchase consideration	(0.24)	-
	Purchase consideration paid on account of business combination	(4.76)	(992.00)
	Purchase of current investments	(3,268.47)	(2,288.33)
	Proceeds from sale of current investments	2,047.71	2,800.00
	Interest received	18.12	3.92
	Proceeds from maturity of deposits (having original maturity of more than three months)	16.12	113.69
	Net investments in deposits (having original maturity of more than three months)	(23.06)	(50.77)
	Net cash flows (used in) from investing activities (B)	**(1,446.89)**	**(836.88)**
C	**Cash flows from financing activities**		
	Proceeds from exercise of options under RSU 2020 scheme	9.00	0.01
	Proceeds/(Repayment) of borrowings	(17.21)	65.19
	Principal payment of lease liabilities	(363.91)	(395.98)
	Interest paid on lease liabilities	(122.85)	(94.80)
	Payment of dividend	(207.33)	-
	Proceeds from issuance of equity instruments to non-controlling interest	3.59	65.59
	Interest paid on borrowings	(7.94)	(13.37)
	Net cash flows (used in) financing activities (C)	**(706.65)**	**(373.36)**
	Net Increase/(Decrease) in cash and cash equivalents (A) + (B) + (C)	**73.29**	**81.06**
	Exchange difference on translation of financial statements of foreign operations	-	20.65
	Net Increase/(Decrease) in cash and cash equivalents	**73.29**	**101.71**
	Cash and cash equivalents at the beginning of the period	**547.84**	**394.76**
	Add: Cash and cash equivalents acquired on account of business combination	-	**6.16**
	Effect of exchange differences on balances with banks in foreign currency	65.54	(0.98)
	Cash and cash equivalents at the end of the period	**686.67**	**501.65**

Note:
The above statement of Cash flows has been prepared under the 'Indirect Method' as set out in Ind AS 7, 'Statement of Cash Flows'.

Metropolis Healthcare Limited Mumbai

Deloitte Haskins & Sells Chartered Accountants LLP Mumbai